solid oral pharmaceutical formulations containing applizierbare rivaroxaban with modified release

• 1. 一种利伐沙班片的制备方法及利伐沙班片、利伐沙班口服药 [P] . 中国专利： CN112402384A . 2021-02-26
• 2. 利伐沙班口服固体制剂及其制备方法 [P] . 中国专利： CN109745295B . 2021.11.12
• 3. SOLID, ORALLY APPLICABLE PHARMACEUTICAL ADMINISTRATION FORMS CONTAINING RIVAROXABAN HAVING MODIFIED RELEASE [P] . CA2591972C . 2012-06-19

  机译： 包含利伐沙班经过改良发布的固体，普遍适用的药物管理表格

• 4. Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release [P] . AU2005324132B2 . 2011-04-28

  机译： 包含具有改良释放的利伐沙班的固体，口服药物给药形式

• 5. SOLID, ORALLY APPLICABLE PHARMACEUTICAL ADMINISTRATION FORMS CONTAINING RIVAROXABAN HAVING MODIFIED RELEASE [P] . PL1830855T3 . 2010-07-30

  机译： 包含利伐沙班经过改良发布的固体，普遍适用的药物管理表格

• 1. Biopharmaceutics classification system(BCS)-based biowaiver for immediate release solid oral dosage forms of moxifloxacin hydrochloride(Moxiflox GPO) manufactured by the Government Pharmaceutical Organization(GPO) [J] . Nawaphon Saelim, Khemjira Suksawaeng, Jutamat Chupan, 亚洲药物制剂科学(英文) . 2016,第001期
• 2. Solid dispersion in the development of a nimodipine delayed-release tablet formulation [J] . Yang Zhao, Tiegang Xin, Tiantian Ye, 亚洲药物制剂科学(英文) . 2014,第001期
• 3. A time-released osmotic pump fabricated by compression-coated method: Formulation screen, mechanism research and pharmacokinetic study [J] . Tiegang Xin, Yang Zhao, Hengpan Jing, 亚洲药物制剂科学(英文) . 2014,第004期
• 4. Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation [J] . Martin C. Michel, Cees Korstanje, Walter Krauwinkel, European urology supplements: official journal of the European Association of Urology . 2005,第2期
• 5. Synthesis and assessment of CTAB and NPE modified organo-montmorillonite for the fabrication of organo-montmorillonite/alginate based hydrophobic pharmaceutical controlled-release formulation [J] . Colloids and Surfaces, B. Biointerfaces . 2020,第期
• 6. Approaches to supply bioequivalent oral solid pharmaceutical formulations through the lifecycles of products: Four-media dissolution monitoring program in Japan [J] . Izutsu Ken-ichi, Abe Yasuhiro, Yoshida Hiroyuki Journal of drug delivery science and technology . 2020,第1期
• 7. Formulation, characterisation and evaluation of modified release microparticles for oral drugdelivery [C] . Richard A. Kendall, Sudaxshina Murdan, Abdul W. Basit Annual meeting exposition of the Controlled Release Society . 2005
• 8. 1. Development of hot-melt pan-coating, application to sustained-release capsules and tamper resistant-coating. 2. Formulation of verapamil hydrogen chloride and diltiazem hydrogen chloride semisolid matrix capsules. 3. Novel sustained release tablet of glipizide: Compression of coated drug beads, formulation, dissolution, and convolution. 4. Verapamil sustained release: New formulation and convolution. [D] . Nguyen, Chien Ngoc. 2006
• 9. Study of Nimesulide Release from Solid Pharmaceutical Formulations in Tween 80 Solutions [O] . Stefana-Oana Purcaru, Mihaela Ionescu, Cristina Raneti, 2010
• 10. A dissolução in vitro na previsão da absorção oral de fármacos em formas farmacêuticas de liberação modificada Dissolution studies in vitro as a prognostic tool for oral absorption of modified release pharmaceutical dosage forms [O] . Rui Manadas, Maria Eugénia Pina, Francisco Veiga 2002
• 11. Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation [R] . 1997

• 1. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon [J] . Aldo Roda ,Patrizia Simoni ,Maria Magliulo . 世界胃肠病学杂志：英文版 . 2007,第7期
• 2. Comparison on the Pharmacokinetics and Weight Reduction of Clobenzorex Slow Release and Immediate Release Formulations in Obese Patients [J] . Federico Argüelles-Tello ,Miriam del C.Carrasco-Portugal ,Norma A.Carrasco-Portugal . 药理与制药（英文） . 2013,第2期
• 3. 新型口服抗凝药利伐沙班与华法林预防非瓣膜病心房颤动卒中的临床对比 [C] . 贾丹 ,杨柏松 . 2015临床急症经验交流高峰论坛 . 2015
• 4. 口服利伐沙班患者的消化道出血临床分析 [A] . 杨春晓 . 2021